Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
17 hedge funds and large institutions have $5.66M invested in Interpace Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
8% more capital invested
Capital invested by funds: $5.26M → $5.66M (+$400K)
6% less funds holding
Funds holding: 18 → 17 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$338K |
| 2 |
MPI
Mairs & Power Inc
St Paul,
Minnesota
|
+$39K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.8K |
| 5 |
AF
Allworth Financial
Folsom,
California
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$463K |
| 2 |
WP
WealthSource Partners
San Luis Obispo,
California
|
-$24K |
| 3 |
VF
Virtu Financial
New York
|
-$23K |
| 4 |
MWM
Merriman Wealth Management
Seattle,
Washington
|
-$14.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$12K |
IDXG Hedge Fund Activity: Q3 2019 in Review
17 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2019, worth a combined $5.66M — up 7.6% from $5.26M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IDXG and 4 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.
The largest buyer was Perkins Capital Management, adding an estimated $338K. The largest seller was Stonepine Capital Management, cutting an estimated $463K.
- 17 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2019, down from 18 in Q2 2019.
- Funds reported $5.66M of Interpace Biosciences, Inc. Common Stock stock for Q3 2019, up 7.6% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2019 and 5 closed out, a net change of -1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2019 was Perkins Capital Management, an estimated $338K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2019 was Stonepine Capital Management, an estimated $463K sold.
Based on aggregated 13F filings for Q3 2019.